Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.13
IART's Cash to Debt is ranked lower than
93% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. IART: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
IART' s 10-Year Cash to Debt Range
Min: 0.1  Med: 0.69 Max: No Debt
Current: 0.13
Equity to Asset 0.44
IART's Equity to Asset is ranked lower than
78% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. IART: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
IART' s 10-Year Equity to Asset Range
Min: 0.29  Med: 0.57 Max: 0.97
Current: 0.44
0.29
0.97
Interest Coverage 2.98
IART's Interest Coverage is ranked lower than
95% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. IART: 2.98 )
Ranked among companies with meaningful Interest Coverage only.
IART' s 10-Year Interest Coverage Range
Min: 1.58  Med: 6.33 Max: 9999.99
Current: 2.98
1.58
9999.99
F-Score: 6
Z-Score: 2.83
M-Score: -2.57
WACC vs ROIC
6.80%
4.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.77
IART's Operating margin (%) is ranked higher than
64% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. IART: 7.77 )
Ranked among companies with meaningful Operating margin (%) only.
IART' s 10-Year Operating margin (%) Range
Min: -129.25  Med: 8.06 Max: 21.36
Current: 7.77
-129.25
21.36
Net-margin (%) 4.24
IART's Net-margin (%) is ranked higher than
58% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. IART: 4.24 )
Ranked among companies with meaningful Net-margin (%) only.
IART' s 10-Year Net-margin (%) Range
Min: -249.02  Med: 4.60 Max: 31.32
Current: 4.24
-249.02
31.32
ROE (%) 5.83
IART's ROE (%) is ranked higher than
57% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. IART: 5.83 )
Ranked among companies with meaningful ROE (%) only.
IART' s 10-Year ROE (%) Range
Min: -41.36  Med: 8.16 Max: 19.5
Current: 5.83
-41.36
19.5
ROA (%) 2.58
IART's ROA (%) is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. IART: 2.58 )
Ranked among companies with meaningful ROA (%) only.
IART' s 10-Year ROA (%) Range
Min: -39.04  Med: 3.57 Max: 16.66
Current: 2.58
-39.04
16.66
ROC (Joel Greenblatt) (%) 11.51
IART's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. IART: 11.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IART' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80.36  Med: 16.55 Max: 72.39
Current: 11.51
-80.36
72.39
Revenue Growth (3Y)(%) 2.10
IART's Revenue Growth (3Y)(%) is ranked lower than
55% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. IART: 2.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IART' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.2  Med: 22.10 Max: 55.2
Current: 2.1
-3.2
55.2
EBITDA Growth (3Y)(%) 2.10
IART's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. IART: 2.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IART' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -37.7  Med: 10.40 Max: 35.2
Current: 2.1
-37.7
35.2
EPS Growth (3Y)(%) 2.70
IART's EPS Growth (3Y)(%) is ranked higher than
54% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. IART: 2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IART' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.7  Med: -1.80 Max: 27.1
Current: 2.7
-31.7
27.1
» IART's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

IART Guru Trades in Q3 2014

Joel Greenblatt 127,001 sh (New)
Paul Tudor Jones 7,700 sh (+28.33%)
Richard Snow 104,765 sh (+7.57%)
Ken Fisher 549,015 sh (+3.15%)
David Dreman 117,456 sh (+1.30%)
Robert Olstein 55,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

IART Guru Trades in Q4 2014

Jim Simons 5,400 sh (New)
Richard Snow 191,850 sh (+83.12%)
Paul Tudor Jones 9,361 sh (+21.57%)
David Dreman 124,944 sh (+6.38%)
Robert Olstein 57,000 sh (+3.64%)
Ken Fisher 537,125 sh (-2.17%)
Joel Greenblatt 18,049 sh (-85.79%)
» More
Q1 2015

IART Guru Trades in Q1 2015

Paul Tudor Jones 200,000 sh (+2036.52%)
Jim Simons 64,330 sh (+1091.30%)
David Dreman 135,688 sh (+8.60%)
Robert Olstein 60,000 sh (+5.26%)
Joel Greenblatt Sold Out
Ken Fisher 520,200 sh (-3.15%)
Richard Snow 180,480 sh (-5.93%)
» More
Q2 2015

IART Guru Trades in Q2 2015

Ken Fisher 514,582 sh (-1.08%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 52.80
IART's P/E(ttm) is ranked lower than
77% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. IART: 52.80 )
Ranked among companies with meaningful P/E(ttm) only.
IART' s 10-Year P/E(ttm) Range
Min: 15.25  Med: 31.54 Max: 80.26
Current: 52.8
15.25
80.26
Forward P/E 17.83
IART's Forward P/E is ranked higher than
64% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.26 vs. IART: 17.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 52.60
IART's PE(NRI) is ranked lower than
77% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.30 vs. IART: 52.60 )
Ranked among companies with meaningful PE(NRI) only.
IART' s 10-Year PE(NRI) Range
Min: 15.17  Med: 31.83 Max: 79.81
Current: 52.6
15.17
79.81
P/B 3.06
IART's P/B is ranked higher than
50% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. IART: 3.06 )
Ranked among companies with meaningful P/B only.
IART' s 10-Year P/B Range
Min: 1.21  Med: 2.34 Max: 5.46
Current: 3.06
1.21
5.46
P/S 2.24
IART's P/S is ranked higher than
59% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. IART: 2.24 )
Ranked among companies with meaningful P/S only.
IART' s 10-Year P/S Range
Min: 0.79  Med: 1.67 Max: 4.96
Current: 2.24
0.79
4.96
PFCF 35.24
IART's PFCF is ranked lower than
61% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 30.88 vs. IART: 35.24 )
Ranked among companies with meaningful PFCF only.
IART' s 10-Year PFCF Range
Min: 6.16  Med: 23.79 Max: 235.39
Current: 35.24
6.16
235.39
POCF 21.31
IART's POCF is ranked higher than
50% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.63 vs. IART: 21.31 )
Ranked among companies with meaningful POCF only.
IART' s 10-Year POCF Range
Min: 5.38  Med: 18.93 Max: 31.1
Current: 21.31
5.38
31.1
EV-to-EBIT 35.71
IART's EV-to-EBIT is ranked lower than
70% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 21.84 vs. IART: 35.71 )
Ranked among companies with meaningful EV-to-EBIT only.
IART' s 10-Year EV-to-EBIT Range
Min: -235.1  Med: 22.45 Max: 609.4
Current: 35.71
-235.1
609.4
Shiller P/E 55.01
IART's Shiller P/E is ranked lower than
73% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 30.75 vs. IART: 55.01 )
Ranked among companies with meaningful Shiller P/E only.
IART' s 10-Year Shiller P/E Range
Min: 16.16  Med: 35.71 Max: 136.84
Current: 55.01
16.16
136.84
Current Ratio 4.12
IART's Current Ratio is ranked higher than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. IART: 4.12 )
Ranked among companies with meaningful Current Ratio only.
IART' s 10-Year Current Ratio Range
Min: 0.81  Med: 4.38 Max: 20.74
Current: 4.12
0.81
20.74
Quick Ratio 2.28
IART's Quick Ratio is ranked higher than
53% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. IART: 2.28 )
Ranked among companies with meaningful Quick Ratio only.
IART' s 10-Year Quick Ratio Range
Min: 0.46  Med: 2.72 Max: 19.26
Current: 2.28
0.46
19.26
Days Inventory 232.91
IART's Days Inventory is ranked lower than
75% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.01 vs. IART: 232.91 )
Ranked among companies with meaningful Days Inventory only.
IART' s 10-Year Days Inventory Range
Min: 112.73  Med: 199.12 Max: 229.69
Current: 232.91
112.73
229.69
Days Sales Outstanding 48.87
IART's Days Sales Outstanding is ranked higher than
79% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. IART: 48.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
IART' s 10-Year Days Sales Outstanding Range
Min: 50.48  Med: 63.64 Max: 80.8
Current: 48.87
50.48
80.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.18
IART's Price/Projected FCF is ranked lower than
56% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. IART: 2.18 )
Ranked among companies with meaningful Price/Projected FCF only.
IART' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 1.43 Max: 10.03
Current: 2.18
0.62
10.03
Price/Median PS Value 1.35
IART's Price/Median PS Value is ranked lower than
64% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. IART: 1.35 )
Ranked among companies with meaningful Price/Median PS Value only.
IART' s 10-Year Price/Median PS Value Range
Min: 0.58  Med: 1.90 Max: 11.02
Current: 1.35
0.58
11.02
Earnings Yield (Greenblatt) (%) 2.80
IART's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. IART: 2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IART' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 4.40 Max: 9.4
Current: 2.8
0.2
9.4
Forward Rate of Return (Yacktman) (%) -12.33
IART's Forward Rate of Return (Yacktman) (%) is ranked lower than
84% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.14 vs. IART: -12.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IART' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -17.6  Med: 21.25 Max: 1210.5
Current: -12.33
-17.6
1210.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IL3.Germany,
Integra Lifesciences Holdings Corp was incorporated in Delaware in 1989. The Company develops, manufactures and market cost-effective surgical implants and medical instruments. Its products are used mainly in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through various distribution channels. The Company currently manufactures and sells its products in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The Company has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, tissue ablation equipment, intracranial monitoring equipment, cranial stabilization equipment, and cerebral spinal fluid management devices. It sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit. It sells its products through directly employed sales representatives. U.S. Extremities; the Company define extremity reconstruction to mean the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee, and the hand, wrist, elbow and shoulder. Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. The Company sells its products through a direct sales organization and through specialty distributors focused on their respective surgical disciplines. Its U.S. Instruments business portfolio includes over 60,000 instrument patterns and surgical products, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. Its brands includes Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract. The Company's U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as differentiated offering of related orthobiologics. This segment also includes private-label sales of a broad set of its regenerative medicine technologies. The International segment sells similar products, but they are managed through Europe, Middle East and Africa, Latin/South America, Asia-Pacific, Australia, New Zealand and Canada. The Company's trademarks include AccuDrain, Accell, Accell Evo3, Advansys, Atoll , Ascension, Bold, Budde, Buzz , Camino, CRW, Coral, CUSA, Daytona, DenLite, Dur
» More Articles for NAS:IART

Headlines

Articles On GuruFocus.com
SeaSpine: A Pure-Play Medical Spinoff Jul 22 2015 
WEEKLY CFO SELLS HIGHLIGHT: LMT, WCG, GRPN, IART, CNK Aug 26 2013 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 10,0 Mar 09 2011 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 125,100 Shares Mar 08 2011 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 5,32 Dec 08 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Dec 03 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Nov 04 2010 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 100, Nov 04 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Oct 28 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 10-Q, Quarterly Report Jul 31 2015
Integra upgraded by JP Morgan Jul 31 2015
Edited Transcript of IART earnings conference call or presentation 30-Jul-15 12:30pm GMT Jul 30 2015
Integra LifeSciences Holdings Corp Earnings Call scheduled for 8:30 am ET today Jul 30 2015
Integra beats Street 2Q forecasts Jul 30 2015
Integra beats Street 2Q forecasts Jul 30 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Results of Operations and Financial... Jul 30 2015
Integra LifeSciences Reports Second Quarter 2015 Financial Results Jul 30 2015
Broadfin Capital and Bridger Management Think SeaSpine Holdings Corp (SPNE) Is Oversold Jul 23 2015
Integra LifeSciences Completes Acquisition of TEI Biosciences and TEI Medical Jul 20 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of... Jul 20 2015
Integra LifeSciences Completes Acquisition of TEI Biosciences and TEI Medical Jul 20 2015
Integra LifeSciences to Host Its Second Quarter 2015 Earnings Results Conference Call on July 30,... Jul 15 2015
Integra LifeSciences to Host Its Second Quarter 2015 Earnings Results Conference Call on July 30,... Jul 15 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of... Jul 08 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 07 2015
Integra LifeSciences (IART) Closes SeaSpine Spin-Off - Analyst Blog Jul 02 2015
SeaSpine Holdings Corporation Begins Trading on NASDAQ Jul 02 2015
Integra LifeSciences Completes Spin-Off of SeaSpine Jul 01 2015
Integra LifeSciences Completes Spin-Off of SeaSpine Jul 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK